<DOC>
	<DOCNO>NCT03066258</DOCNO>
	<brief_summary>Excessive vascular endothelial growth factor ( VEGF ) play key part promote neovascularization edema neovascular ( wet ) age-related macular degeneration ( nAMD ) . VEGF inhibitor ( anti-VEGF ) , include ranibizumab ( LUCENTIS® , Genentech ) aflibercept ( EYLEA® , Regeneron ) , show safe effective treat nAMD demonstrate improvement vision . However , anti-VEGF therapy administer frequently via intravitreal injection significant burden patient . RGX-314 recombinant adeno-associated virus ( AAV ) gene therapy vector carry cod sequence soluble anti-VEGF protein . The long-term , stable delivery therapeutic protein follow 1 time gene therapy treatment nAMD could potentially reduce treatment burden currently available therapy maintain vision favorable benefit : risk profile .</brief_summary>
	<brief_title>RGX-314 Gene Therapy Neovascular AMD Trial</brief_title>
	<detailed_description>This Phase I , open-label , multiple-cohort , dose-escalation study design evaluate safety tolerability RGX-314 gene therapy subject previously treat nAMD . Three dos study approximately 18 subject . Subjects meet inclusion/exclusion criterion anatomic response initial anti VEGF injection receive single dose RGX-314 administer subretinal delivery . RGX-314 us AAV8 vector contain gene encodes monoclonal antibody fragment bind neutralizes VEGF activity . Safety primary focus initial 24 week RGX-314 administration ( primary study period ) . Following completion primary study period , subject continue assess 104 week follow treatment RGX-314 .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>1 . Patients ≥ 50 year diagnosis subfoveal CNV secondary AMD study eye receive prior intravitreal antiVEGF therapy . 2 . BCVA ≤20/100 ≥20/400 ( ≤65 ≥35 Early Treatment Diabetic Retinopathy Study [ ETDRS ] letter ) first patient cohort follow BCVA ≤20/63 ≥20/400 ( ≤75 ≥35 ETDRS letter ) rest cohort . 3 . History need response antiVEGF.therapy . 4 . Response antiVEGF trial entry ( assess SDOCT week 1 ) 5 . Must pseudophakic ( status post cataract surgery ) study eye . 6 . AST/ALT &lt; 2.5 × ULN ; TB &lt; 1.5 × ULN ; PT &lt; 1.5 × ULN ; Hb &gt; 10 g/dL ( male ) &gt; 9 g/dL ( female ) ; Platelets &gt; 100 × 10^3/µL ; eGFR &gt; 30 mL/min/1.73 m^2 7 . Must willing able provide write , sign informed consent . 1 . CNV macular edema study eye secondary cause AMD . 2 . Any condition prevent visual acuity improvement study eye , eg , fibrosis , atrophy , retinal epithelial tear center fovea . 3 . Active history retinal detachment study eye . 4 . Advanced glaucoma study eye . 5 . History intravitreal therapy study eye , intravitreal steroid injection investigational product , antiVEGF therapy , 6 month prior screen . 6 . Presence implant study eye screening ( exclude intraocular lens ) . 7 . Myocardial infarction , cerebrovascular accident , transient ischemic attack within past 6 month . 8 . Uncontrolled hypertension ( systolic blood pressure [ BP ] &gt; 180 mmHg , diastolic BP &gt; 100 mmHg ) despite maximal medical treatment .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>nAMD</keyword>
	<keyword>wet AMD</keyword>
	<keyword>gene therapy</keyword>
</DOC>